查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美藥物動力學服務市場預測至 2031 年 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶
市場調查報告書
商品編碼
1597063

北美藥物動力學服務市場預測至 2031 年 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶

North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 87 Pages | 訂單完成後即時交付

價格

2023年北美藥物動力學服務市值為3.7536億美元，預計2031年將達到6.9277億美元；預計2023年至2031年複合年成長率為8.0%。

藥物動力學研究應用範圍的擴大推動北美藥物動力學服務市場

藥物動力學研究用於確定多個參數，例如人體等效劑量 (HED) 水平、未觀察到效應水平 (NOEL) 和藥物動力學/藥效學測試。進行的任何臨床前計劃的主要重點是支持對藥物動力學研究測試的安全有效劑量範圍的分析。多項毒理學研究對 NOEL（即不會產生不良反應的最高劑量）進行了資料分析。如果缺乏臨床藥物動力學資料，則該劑量水平會在比較體表面積的基礎上進一步轉換為 HED 水平。了解潛在候選藥物的藥物動力學特徵在藥物發現計劃中起著重要作用。監管機構在推動藥物動力學研究的實施方面發揮著重要作用。這些研究也有助於最佳化為住院患者提供的藥物護理服務。 PK模型常用於確定藥物暴露量、藥物濃度以分析最佳劑量，並分析藥物在人體內的分佈。醫療保健提供者實施 PK 原則來設計監測藥物濃度、某些藥物的劑量，最大限度地提高預期治療效果並最大限度地減少毒性。

北美藥物動力學服務市場概況

美國佔據北美藥物動力學服務市場的最大佔有率。該國已成為領先的臨床研究目的地；它約佔全球臨床試驗總數的 50%。成熟的醫療基礎設施、快速的核准時間表和有利的監管框架為藥物研究公司進行臨床試驗創造了有利的環境。此外，在美國進行的試驗中產生的資料在全球範圍內被接受。根據世界衛生組織 (WHO) 的報告，美國 2021 年登記的臨床試驗數量最多（157,618 項）。

北美藥物動力學服務市場收入及 2031 年預測（百萬美元）

北美藥物動力學服務市場細分

北美藥物動力學服務市場分為藥物類型、服務類型、治療應用、最終用戶和國家。

根據藥物類型，北美藥物動力學服務市場分為小分子、大分子和疫苗。 2023 年，小分子細分市場佔據最大的市場佔有率。

從服務類型來看，北美藥物動力學服務市場分為臨床前ADME和人體研究、PK/PD分析和報告、給藥模擬、風險分析等。 2023 年，臨床前 ADME 和人體研究領域佔據最大的市場佔有率。

依治療應用，北美藥物動力學服務市場分為腫瘤學、傳染病、神經系統疾病、自體免疫疾病、婦科疾病、心血管疾病、呼吸系統疾病等。 2023 年，腫瘤學領域佔據最大的市場佔有率。

依最終用戶分類，北美藥物動力學服務市場分為製藥和生物技術公司、合約研究組織等。 2023 年，合約研究組織細分市場佔據最大的市場佔有率。

依國家/地區分類，北美藥物動力學服務市場分為美國、加拿大和墨西哥。 2023 年，美國在北美藥物動力學服務市場佔有率中佔據主導地位。

查爾斯河實驗室國際公司； Eurofins Scientific SE； Evotec SE；塞塔拉公司； Parexel國際公司；賽默飛世爾科技公司；艾倫特；太平洋生物實驗室；和 SGS SA 是北美藥物動力學服務市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美藥物動力學服務市場格局

  • PEST分析

第 5 章：北美藥物動力學服務市場 - 主要市場動態

  • 市場促進因素
    • 慢性病和傳染病的盛行率上升
    • 擴大藥物動力學研究的應用範圍
    • 將藥物動力學服務外包給 CRO
  • 市場限制
    • 新興國家藥物動力學服務提供者的覆蓋範圍有限
  • 市場機會
    • 擴大採用體內和體外模型來了解藥物動力學的變異性
  • 未來趨勢
    • 藥物動力學服務中越來越多採用巨量資料分析
  • 促進因素和限制的影響：

第 6 章：藥物動力學服務市場 - 北美分析

  • 北美藥物動力學服務市場收入，2021-2031

第 7 章：北美藥物動力學服務市場分析 - 按藥物類型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 8 章：北美藥物動力學服務市場分析 - 按服務類型

  • 概述
  • 臨床前 ADME 和人體研究
  • PK/PD 分析和報告
  • 劑量模擬
  • 風險分析
  • 其他

第 9 章：北美藥物動力學服務市場分析 - 按治療應用

  • 腫瘤學
  • 傳染病
  • 神經系統疾病
  • 自體免疫疾病
  • 婦科疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 其他

第 10 章：北美藥物動力學服務市場分析 - 按最終用戶

  • 製藥和生物技術公司
  • 合約研究組織
  • 其他

第 11 章：北美藥物動力學服務市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 12 章：公司簡介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA

第 13 章：附錄

Product Code: BMIRE00030931

The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.

Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

North America Pharmacokinetics Services Market Overview

The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.

North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

North America Pharmacokinetics Services Market Segmentation

The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Pharmacokinetics Services Market Landscape

  • 4.1 PEST Analysis

5. North America Pharmacokinetics Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 5.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 5.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 5.2 Market Restraints
    • 5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 5.4 Future Trend
    • 5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 5.5 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - North America Analysis

  • 6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

7. North America Pharmacokinetics Services Market Analysis - by Drug Type

  • 7.1 Overview
  • 7.2 Small Molecule
    • 7.2.1 Overview
    • 7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Large Molecule
    • 7.3.1 Overview
    • 7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Vaccines
    • 7.4.1 Overview
    • 7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Pharmacokinetics Services Market Analysis - by Service Type

  • 8.1 Overview
  • 8.2 Pre-Clinical ADME and Human Studies
    • 8.2.1 Overview
    • 8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 PK/PD Analysis and Reporting
    • 8.3.1 Overview
    • 8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Dosing Simulations
    • 8.4.1 Overview
    • 8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Risk Analysis
    • 8.5.1 Overview
    • 8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 9.1 Oncology
    • 9.1.1 Overview
    • 9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Infectious Diseases
    • 9.2.1 Overview
    • 9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Neurological Disorders
    • 9.3.1 Overview
    • 9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Autoimmune Diseases
    • 9.4.1 Overview
    • 9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Gynecological Disorders
    • 9.5.1 Overview
    • 9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 Cardiovascular Diseases
    • 9.6.1 Overview
    • 9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Respiratory Disorders
    • 9.7.1 Overview
    • 9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Pharmacokinetics Services Market Analysis - by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Contract Research Organization
    • 10.2.1 Overview
    • 10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Others
    • 10.3.1 Overview
    • 10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Pharmacokinetics Services Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
      • 11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

  • 12.1 Charles River Laboratories International Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Eurofins Scientific SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Evotec SE
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Certara Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
  • 12.5 Parexel International Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Allucent
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 PACIFIC BIOLABS
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SGS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms for Pharmacokinetic Services Market

List Of Tables

  • Table 1. North America Pharmacokinetics Services Market Segmentation
  • Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Glossary of Terms

List Of Figures

  • Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
  • Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)